X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

PROSTATE CANCER RESEARCH BACKED AT $110M BY HOUSE APPROPRIATIONS COMMITTEE

WASHINGTON, D.C., May 21, 2019 – The House Appropriations Committee is backing a historic $10M increase in funding for the Prostate Cancer Research Program (PCRP). This brings the total PCRP budget proposal at the Department of Defense (DoD) to a program record $110M.

“The fight against prostate cancer has never been so hopeful,” said ZERO CEO and President Jamie Bearse. “This is a major victory for patients and families that are in the fight right now as this funding will ensure as many as a dozen new brilliant ideas could become tomorrow’s treatments and diagnostic tools.”

The $10M increase has been a major focus of ZERO’s champion advocates for the past year as hundreds of prostate cancer patients, family members, doctors, and advocates from around the U.S. stormed Capitol Hill in February during the ZERO Prostate Cancer Summit in Washington, D.C.

“Our champions’ objective on Capitol Hill was to educate elected officials about the disease and emphasize how we can reduce death from prostate cancer and the pain and suffering endured by patients by increasing research funding,” said Bearse. “It’s the result of hard work on behalf of thousands of selfless and caring individuals.”

U.S. Reps. Sanford Bishop (D-GA) and Peter King (R-NY) took ZERO’s mission to heart and lead a letter, which thanks to ZERO advocates around the country, secured 157 signatures from Members of Congress supporting $110M in PCRP funding.

Research funding at the PCRP is part of the Congressionally Directed Medical Research Program (CDMRP) and is unique in a way that it incorporates patients’ perspectives on projects receive grants. During the last eight years, the PCRP has funded three treatments for advanced prostate cancer and a tool to better determine the aggressiveness of the disease in each patient. The CDMRP is host to innovative breakthroughs for many diseases and conditions impacting both active-duty service men and women as well as military families.

The bill will now to be sent to the full House Of Representatives, where it will be brought to a vote either as its own bill or as part of a larger appropriations bill. The U.S. Senate and House will likely release their conference report on the 2020 Defense Appropriations Bill later this year with the final appropriation for the program.


About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 86 cents of every dollar to research and programs. For more information, visit www.zerocancer.org.